Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-09-03
2008-12-30
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S520000, C549S442000, C558S410000
Reexamination Certificate
active
07470723
ABSTRACT:
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.
REFERENCES:
patent: 4118742 (1978-10-01), Paget et al.
patent: 4492708 (1985-01-01), Spitzer
patent: 5414008 (1995-05-01), Muller et al.
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5929117 (1999-07-01), Muller et al.
patent: 6130226 (2000-10-01), Muller et al.
patent: 6262101 (2001-07-01), Muller et al.
patent: 2001/0056107 (2001-12-01), Muller et al.
patent: 2005/0107339 (2005-05-01), Muller et al.
patent: 0091795 (1983-10-01), None
patent: 0316594 (1989-05-01), None
patent: 58188868 (1983-11-01), None
patent: 05066591 (1993-03-01), None
patent: WO 96/21435 (1996-07-01), None
patent: WO 98/06692 (1998-02-01), None
patent: WO 00/01387 (2000-01-01), None
patent: WO 2004/078144 (2004-09-01), None
Bedford et al. 1996, Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bioorganic & Medicinal Chemistry Lett. 6(2):157-160.
Chen et al., 2000, Preparation of New Anti-Tubulin Ligands through a Dual-Mode, Addition-Elimination Reaction to a Bromo-Substituted α, β-Unsaturated Sulfoxide. J. Org. Chem. 65:8811-8815.
Cummins et al., 1971, Aust. J. Chem., v. 24(11), pp. 2257-2266.
Cushman et al., 1993, Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem. 35(12):2293-2306.
Danion et al., 1972, Tetrahedron, v. 28(15), pp. 4223-4229 (including English language abstract).
Fischer et al., 1993, J. Organomet. Chem., v. 454(1-2), pp. 133-149 (including English language abstract).
Groundwater et al., 1992, Electrocyclic Aromatic Substitution by Nitrile Ylides to Give 3H-2-Benzazepines: Substituent Effects and Mechanism. Tetrahedron, 48(37):7951-7964.
Gwaltney et al., 2001, Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg Med Chem Lett. 11(7):871-874.
Hamel E. 1996, Antimitotic natural products and their interactions with tubulin. Med Res Rev. 16(2):207-231.
Hastie SB. 1991, Interactions of colchicine with tubulin. Pharmacol Ther. 51(3):377-401.
Ilg et al., 2001, Organometallics, v. 20(17), pp. 3782-3794.
Laubender et al., 1998, Angewandte Chemie, Int. Ed., v. 37(1/2), pp. 150-152.
Laubender et al., 1999, Chemistry-A European Journal, v. 5(10), pp. 2937-2946.
Li et al., 2002, Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg Med Chem Lett. 12(3):465-469.
Liou et al., 2002, Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem. 45(12):2556-2562.
Luduena et al., 1991, Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol Ther. 49(1-2):133-152.
McGown and Fox, 1990, Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol. 26(1):79-81.
Medarde et al., 1999, Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg Med Chem Lett. 9(16):2303-2308.
Mu et al., 2001, Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. J Med Chem. 44(3):441-452.
Nam et al., 2002, Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenomes and related analogues. Bioorg Med Chem Lett. 12(15):1955-1958.
Ohsumi et al., 1998, Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem. 41(16):3022-3032.
Ohsumi et al., 1998, Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg Med Chem Lett. 8(22):3153-3158.
Pac et al., 1984, J. Org. Chem., v. 49(1), pp. 26-34 (1984).
Pettit et al., 1989, Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45(2):209-211.
Pettit et al., 1998, Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem. 41(10):1688-1695.
Pettit et al., 1999, Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4. J Med Chem. 42(8):1459-1465.
Pettit et al., 2000, Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. J Med Chem. 43(14):2731-2737.
Pettit et al., 2002, Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 45(12):2534-2542.
Profitt et al., 1975, A Reagent for the α, β Reduction of Conjugated Nitriles. J. Org. Chem., 40(1), pp. 127-128.
Shirai et al., 1998, Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 8(15):1997-2000.
Thorpe PE, 2004, Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 10(2):415-427.
Update on Spindle Poisons—Part II: Vinca Alkaloids and Analogs/Formulations. Future Oncology, vol. 6 (12):1457-1484 (2002).
Update on Spindle Poisons—Part III: Novel Agents in Development. Future Oncology, 7 (1/2):1485-1528 (2002).
Verdier-Pinard et al., 1998, Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol. 53(1):62-76.
Wang et al., 2002, Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem. 45(8):1697-1711.
Yoon et al., 2002, CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther. 1(6):393-404.
Chen Roger
Man Hon-Wah
Muller George W.
Payvandi Faribourz
Robarge Michael J.
Celgene Corporation
Jones Day
Kosack Joseph R
Shiao Rei-tsang
LandOfFree
Diphenylethylene compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylethylene compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylethylene compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4029278